Dr. Candice Jamois is pharmacometrician in Clinical Pharmacology, at F. Hoffman La Roche Ltd.
After her PharmD exam dedicated to pharmacokinetic-pharmacodynamic (PK-PD) modeling of the EEG effect of imipenem in rats, Dr. Jamois spent a 4-year residency program in Paris Hospitals (i.e., André Mignot, Paul Brousse) where she specialized in biochemistry, PKPD modeling, toxicology and regulatory.
Dr Jamois has been working for 16 years in Industry in Clinical Pharmacology, supporting various disease areas such as cardiovascular, neuroscience, oncology and auto-immune diseases. Since 2012, she is mainly dedicated to Oncology and had worked on the registration of several monoclonal antibodies (mAb) such as the anti-CD20 molecules, rituximab (Rituxan®, Rituxan Hyacela®) and obinutuzumab (GAZYVA/ARO®) in Chronic Lymphocytic Leukemia, Follicular Lymphoma and Diffuse Large B-cell Lymphoma.
She is interesting in understanding the source of variability in clinical response and how drug exposure contributes to it. In cancer patients, the mAb clearance can be affected by the natural progression of the disease and by the PD and therapeutic effects of the drug itself, which has some implication for exposure-response analysis; this is of particular interest for her.
